First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)

Trial Profile

First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs ReN 003 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man
  • Sponsors ReNeuron
  • Most Recent Events

    • 26 Mar 2018 According to a ReNeuron media release, short term read-outs from this trial is expected in the first half of 2019.
    • 30 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.
    • 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top